Citigroup
IOVA icon

Citigroup’s Iovance Biotherapeutics IOVA Stock Holding History

Citigroup’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$228K – 5773
2023
Q3 		$228K Hold
50,000
– – ﹤0.01% 3594
2023
Q2 		$352K Sell
50,000
-40,000
-44% -$286K ﹤0.01% 3597
2023
Q1 		$550K Buy
+90,000
New +$621K ﹤0.01% 3065
2022
Q3 		– Sell
-400,000
Closed -$4.42M – 6071
2022
Q2 		$4.42M Buy
+400,000
New +$5.24M ﹤0.01% 1599

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Citigroup's IOVA Position: Q2 2026 in Review

Citigroup increased its Iovance Biotherapeutics (IOVA) stake by 979% in Q2 2026, buying an estimated $3.04M and bringing the position to 882,132 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Citigroup first reported a position in IOVA in Q2 2015 and has held it in 45 quarters since. The position peaked at $8M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Citigroup held 882,132 shares of Iovance Biotherapeutics worth $3.67M as of Q2 2026.
  • Citigroup bought 800,407 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.04M.
  • Iovance Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2409 holding.
  • Citigroup first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 45 quarters since.
  • Citigroup's Iovance Biotherapeutics position peaked at $8M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.